切换导航
  • 比较产品
我的购物车

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

ImmunoCult™人CD3/CD28/CD2 T细胞激活剂

cGMP，人T细胞激活和扩增试剂
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #100-0785_C

cGMP，人T细胞激活和扩增试剂

产品优势

  • 使用符合cGMP相关标准生产的激活剂激活的T细胞可安心用于临床应用
  • 无需使用磁珠、饲养层细胞或抗原即可实现强劲的T细胞激活
  • 提供温和的激活刺激，在激活与扩增T细胞同时保持高活率
  • 高度稳定、过滤灭菌的可溶性试剂
main product photo
总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

无需使用磁珠、饲养层细胞或抗原，即可实现强劲的人T细胞激活与扩增。

该产品的温和激活刺激能确保T细胞的高活率，激活后的细胞可在ImmunoCult™-XF（按cGMP相关法规与指南生产的高性能扩增培养基）中进一步扩增。ImmunoCult™人CD3/CD28/CD2 T细胞激活剂由可溶性抗体复合物组成，能结合并交联CD3、CD28及CD2细胞表面配体，为T细胞培养与激活提供必需的关键信号与共刺激信号。

ImmunoCult™人CD3/CD28/CD2 T细胞激活剂专为细胞治疗临床研究应用设计，根据USP<1043>和/或PH. EUR. 5.2.12的框架标准，可作为辅助材料（AM）使用。STEMCELL可协助您将该试剂在获批的新药研究（IND）申请、生物制品许可申请（BLA）或临床试验申请（CTA）中申报作为辅助材料（AM）。点击此处进一步了解我们如何支持您的法规需求。

该产品的温和激活刺激能确保T细胞的高活率，激活后的细胞可在ImmunoCult™-XF（按cGMP相关法规与指南生产的高性能扩增培养基）中进一步扩增。ImmunoCult™人CD3/CD28/CD2 T细胞激活剂由可溶性抗体复合物组成，能结合并交联CD3、CD28及CD2细胞表面配体，为T细胞培养与激活提供必需的关键信号与共刺激信号。

ImmunoCult™人CD3/CD28/CD2 T细胞激活剂专为细胞治疗临床研究应用设计，根据USP<1043>和/或PH. EUR. 5.2.12的框架标准，可作为辅助材料（AM）使用。STEMCELL可协助您将该试剂在获批的新药研究（IND）申请、生物制品许可申请（BLA）或临床试验申请（CTA）中申报作为辅助材料（AM）。点击此处进一步了解我们如何支持您的法规需求。

该产品的温和激活刺激能确保T细胞的高活率，激活后的细胞可在ImmunoCult™-XF（按cGMP相关法规与指南生产的高性能扩增培养基）中进一步扩增。ImmunoCult™人CD3/CD28/CD2 T细胞激活剂由可溶性抗体复合物组成，能结合并交联CD3、CD28及CD2细胞表面配体，为T细胞培养与激活提供必需的关键信号与共刺激信号。

ImmunoCult™人CD3/CD28/CD2 T细胞激活剂专为细胞治疗临床研究应用设计，根据USP<1043>和/或PH. EUR. 5.2.12的框架标准，可作为辅助材料（AM）使用。STEMCELL可协助您将该试剂在获批的新药研究（IND）申请、生物制品许可申请（BLA）或临床试验申请（CTA）中申报作为辅助材料（AM）。点击此处进一步了解我们如何支持您的法规需求。

无需使用磁珠、饲养层细胞或抗原，即可实现强劲的人T细胞激活与扩增。

该产品的温和激活刺激能确保T细胞的高活率，激活后的细胞可在ImmunoCult™-XF（按cGMP相关法规与指南生产的高性能扩增培养基）中进一步扩增。ImmunoCult™人CD3/CD28/CD2 T细胞激活剂由可溶性抗体复合物组成，能结合并交联CD3、CD28及CD2细胞表面配体，为T细胞培养与激活提供必需的关键信号与共刺激信号。

ImmunoCult™人CD3/CD28/CD2 T细胞激活剂专为细胞治疗临床研究应用设计，根据USP<1043>和/或PH. EUR. 5.2.12的框架标准，可作为辅助材料（AM）使用。STEMCELL可协助您将该试剂在获批的新药研究（IND）申请、生物制品许可申请（BLA）或临床试验申请（CTA）中申报作为辅助材料（AM）。点击此处进一步了解我们如何支持您的法规需求。

 

Contains
• Anti-human CD3 monospecific antibody complex
• Anti-human CD28 monospecific antibody complex
• Anti-human CD2 monospecific antibody complex
• Phosphate buffered-saline (PBS), containing 0.02% TWEEN® 20
 
Subtype
Supplements
 
Cell Type
T Cells, T Cells, CD4+, T Cells, CD8+
 
Species
Human
 
Application
Activation, Cell Culture, Expansion
 
Brand
ImmunoCult
 
Area of Interest
Cancer, Immunology, Cell Therapy Development
 

查看更多 显示更少

实验数据

Activated human T cells clustering together

Figure 1. Morphology of Activated Human T Cells Stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator

A clustered morphology is seen in activated human T cells. Cells were isolated using EasySep™ Human T Cell Isolation Kit, stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator for 3 days in ImmunoCult™-XF supplemented with recombinant human interleukin-2 (rhIL-2).

Flow cytometry data showing human T cell activation assessed by CD25 expression.

Figure 2. Activation of Human T Cells Stimulated with ImmunoCult™ Human CD3/CD28/CD2 Activator.

Human T cells were stimulated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator and cultured in ImmunoCult™-XF. Activation of viable CD4+ and CD8+ T cells were assessed by CD25 expression, using flow cytometry. Following 3 days of culture, the frequency of CD25-positive cells was (A) 91.4% for CD4+ T cells and (B) 87.8% for CD8+ T cells. The gray line depicts day 3 CD4+ and CD8+ T cells cultured without ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator.

Human T cell cumulative fold expansion and activation during a 12-day culture period.

Figure 3. Robust Human T Cell Expansion and High Viability Achieved Using ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator

Human T cells were expanded over 12 days with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator in ImmunoCult™-XF supplemented with rhIL-2. On day 0, 1 x 10^6 isolated human T cells were stimulated with 25 μL of ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator in ImmunoCult™-XF supplemented with rhIL-2.No additional ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator was added during the 12-day culture period (mean ± SD in 3 experiments with 7 donors).

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator
Catalog #
100-0785
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator
Catalog #
100-0785
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area
Workflow Stages

相关材料与文献

技术资料 (6)

Use cGMP-Manufactured ImmunoCult™-XF
Brochure
Use cGMP-Manufactured ImmunoCult™-XF
T Cell Reagents for Your Cellular Therapy Research
Brochure
T Cell Reagents for Your Cellular Therapy Research
Rational Combination of Cancer Therapies with PD1 Axis Blockade
Wallchart
Rational Combination of Cancer Therapies with PD1 Axis Blockade
Production of Chimeric Antigen Receptor T Cells
Wallchart
Production of Chimeric Antigen Receptor T Cells
Advances in Point-of-Care Cell Engineering—What Are You Feeding Your CAR T Cells?
27:57
Webinar
Advances in Point-of-Care Cell Engineering—What Are You Feeding Your CAR T Cells?
Activation, Expansion, and Culture of Human T Cells Using ImmunoCult™ cGMP-Compliant Ancillary Reagents
Scientific Poster
Activation, Expansion, and Culture of Human T Cells Using ImmunoCult™ cGMP-Compliant Ancillary Rea...

文献 (1)

Pharmacological Inhibition of MALT1 Ameliorates Autoimmune Pathogenesis and Can Be Uncoupled From Effects on Regulatory T-Cells. S. Biswas et al. Frontiers in immunology 2022

Abstract

MALT1 forms part of a central signaling node downstream of immunoreceptor tyrosine-based activation motif (ITAM)-containing receptors, across a broad range of immune cell subsets, and regulates NF-$\kappa$B driven transcriptional responses via dual scaffolding-protease activity. Allosteric inhibition of MALT1 activity has demonstrated benefit in animal models of inflammation. However, development of MALT1 inhibitors to treat autoimmune and inflammatory diseases (A&ID) has been hindered by reports linking MALT1 inhibition and genetic loss-of-function to reductions in regulatory T-cell (Treg) numbers and development of auto-inflammatory syndromes. Using an allosteric MALT1 inhibitor, we investigated the consequence of pharmacological inhibition of MALT1 on proinflammatory cells compared to regulatory T-cells. Consistent with its known role in ITAM-driven responses, MALT1 inhibition suppressed proinflammatory cytokine production from activated human T-cells and monocyte-derived macrophages, and attenuated B-cell proliferation. Oral administration of a MALT1 inhibitor reduced disease severity and synovial cytokine production in a rat collagen-induced arthritis model. Interestingly, reduction in splenic Treg numbers was less pronounced in the context of inflammation compared with na{\{i}}ve animals. Additionally in the context of the disease model we observed an uncoupling of anti-inflammatory effects of MALT1 inhibition from Treg reduction with lower systemic concentrations of inhibitor needed to reduce disease severity compared to that required to reduce Treg numbers. MALT1 inhibition did not affect suppressive function of human Tregs in vitro. These data indicate that anti-inflammatory efficacy can be achieved with MALT1 inhibition without impacting the number or function of Tregs further supporting the potential of MALT1 inhibition in the treatment of autoimmune disease."
View publication
View All Publications

更多信息

更多信息
种属 Human
Contains • Anti-human CD3 monospecific antibody complex • Anti-human CD28 monospecific antibody complex • Anti-human CD2 monospecific antibody complex • Phosphate buffered-saline (PBS), containing 0.02% TWEEN® 20
THIS PRODUCT IS MANUFACTURED AND TESTED FOLLOWING RELEVANT CGMPs UNDER A CERTIFIED QUALITY MANAGEMENT SYSTEM. PRODUCT IS FOR INVESTIGATIONAL OR RESEARCH USE. NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. 欲获悉更多关于STEMCELL的质控信息，请访问 WWW.STEMCELL.COM/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.